All Time Record Sales Growth for Unmatched 'Evacuated Cell' Insulation From Very Small Share Structure Company With Only 38 Million OS / 16 Million Float: Innovative Designs, Inc. Stock Symbol: IVDN
Sole Maker of Patented Insultex® Insulation Delivering Construction Cost and Energy Saving Performance Superior to All Competition.
Unique Evacuated Cell House Wrap Material Provides an Unmatched R-6 Rating, Water Vapor, Air & Wind Barrier and Other Important Advantages.
New Board Member is Experienced Real Estate Developer with Relations to Top Homebuilding Names Including D.R. Horton, NVR / Ryan Homes and More.
New Government Building Codes Require Continuous Insulation with Higher Performance and IVDN Meets or Exceeds These Standards Where Many Competitors Now Do Not.
Increased Order Fulfilment Capabilities Recently Added with Plans for Further Enhancement to Handle Increasing Demand.
Sales for the Current 2025 1st Quarter, Still in Progress, Show a Comp Increase in Excess of 7 Times Sales Over the 1st Quarter of 2024.
Over a Quarter of a Million Dollars in Purchase Orders are Currently in the Queue to be Filled.
2024 Fiscal Third Quarter Revenues More Than Doubled Same Period in 2023.
First Nine Months of Fiscal 2024 Delivered a 285% Increase Over 2023.
Accelerating Order Flow and Record Backlog in 2024 vs. No Backlog in 2023.
Innovative Designs, Inc. (Symbol: IVDN), manufactures and markets its unique, patented Insultex® material, a quantum leap forward in insulation as the thinnest, lightest and warmest insulator on the market today. IVDN products deliver optimum warmth and comfort via insulating, windproof and waterproof protection with no animal materials. IVDN holds issued US patents on both the evacuated cell material and its manufacturing process.
For home building, home remodeling and other construction, significant improvements in energy efficiency measures, such as IVDN Insultex House Wrap® can provide, have never been more important. Superior insulation, for heating or cooling, is fast becoming a primary factor in the multi-billion dollar construction and remodeling industry today. In addition to lowering construction costs because additional insulation boards or supports are not needed, Insultex® use results in high energy efficiency and a reduction of greenhouse gas emissions that contribute to the global climate change crisis.
IVDN Insultex House Wrap® delivers an unmatched R-6 rating because of its unique and patented evacuated or vacuum cell structure design. The dedicated IVDN Insultex House Wrap® website explains the scientific principles in detail along with visual aids. Insultex® also provides a moisture barrier and other key benefits that make it simply the best insulation choice available today.
The IVDN Insultex House Wrap ® website may be visited at http://www.insultexhousewrap.com.
Homeowners who upgrade to superior IVDN Insultex House Wrap® insulation may also qualify for substantial tax credits under The Inflation Reduction Act, in addition to enjoying the lower energy bills that result.
As building codes and exterior R-Value requirements are quickly evolving across the country, IVDN distributor Built Link Solutions has proven highly proactive in contacting prospective accounts, notifying them of the cost-effective solution that Insultex House Wrap® provides.
Randy Kimbler, Director of Business Development for Built Link Solutions, stated: 'Insultex House Wrap® is gaining traction in the market as it provides a timely and effective solution. Its cost-effectiveness, innovation, and ability to address today's building challenges are driving positive feedback nationwide.'
For investors, IVDN has a very small share structure with only about 38 million shares outstanding and a public float of about 16 million shares. Also, according to the latest 10-K filing, IVDN Management and Directors are holding over 8 million of these shares making IVDN avery lean stock.
IVDN Welcomes Experienced Real Estate Developer with Relations to Top Homebuilding Names Including D.R. Horton, NVR / Ryan Homes and More
On January 23rd IVDN announced a new addition to the Company's Board of Directors, Mr. John Spagnolo Jr., an accomplished real estate investor and developer. For over 20 years Mr. Spagnolo, Jr. has been successful in building high end homes, residential and commercial properties and other development projects. Most notably, over the course of his career, Mr. Spagnolo, Jr., has nurtured relationships with key contacts at some of the most important companies in the multi-billion-dollar homebuilding and construction industry. These include D.R. Horton, NVR [Ryan Homes], Maronda Homes, Rockford Homes, Fischer Homes, Infinity Custom Homes and more. Regarding his new role on the IVDN Board of Directors, John Spagnolo Jr. stated: 'I am strongly enthusiastic about the sales growth potential of the unique Insultex House Wrap® product in the building and remodeling environment that we see before us today. This is the primary reason I have accepted the offer to join the Innovative Designs team at this time. With its patented evacuated cell design, Insultex House Wrap® is catching on at the go-to solution for all the most important standards of thermal insulation that builders and remodelers must now meet to stay competitive and in compliance with new government building codes. In 2025 and beyond, I believe we can introduce the unmatched advantages of Insultex House Wrap® to building professionals on every level of the industry and I expect that they will want to use this superior insulation solution in significantly increasing quantities.' IVDN sales for the current 2025 1st quarter, which is still in progress, show a comp increase in excess of 7 times sales over the 1st quarter of 2024. In addition, over a quarter of a million dollars in purchase orders are in the queue to be filled.
Innovative Designs Inc. Reports Record Sales Results to Shareholders
On December 30th IVDN reported the following milestones for its fiscal third quarter:
2024 Fiscal Third Quarter Revenues More Than Doubled Same Period in 2023.
First Nine Months of Fiscal 2024 Delivered Over a 285% Increase Over 2023.
Accelerating Order Flow and Record Backlog in 2024 vs. No Backlog in 2023.
Increasing Production Capabilities to Meet Rising Demand.
Plans for Investor Conference Call / Shareholders Meeting in the Company's 2nd Quarter.
Media Contact
Company Name: INNOVATIVE DESIGNS, INC.
Contact Person: Joseph Riccelli, CEO
Email: Send Email
Phone: 412-799-0350
Address:124 Cherry St
City: Pittsburgh
State: Pennsylvania
Country: United States
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
26 minutes ago
- Business Wire
Sonendo Strengthens Leadership Team With Promotion of John McGaugh to Chief Operating Officer
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. ('Sonendo' or the 'Company') (OTC Pink: SONX), a leading dental technology company and developer of the GentleWave® System, today announced the promotion of John McGaugh to Chief Operating Officer. Mr. McGaugh previously held the position of Senior Vice President of Operations. 'Since Sonendo embarked on its strategic reset in early-2024, the Company has stabilized revenue, generated significant leverage in gross margin, and meaningfully lowered total operating expenses, adjusted EBITDA loss and cash burn,' stated Bjarne Bergheim, President and Chief Executive Officer of Sonendo. 'John has been a significant contributor to all those improvements, and we expect he will continue to drive additional operating leverage as the Company continues to execute its plans to achieve profitability. John is a valuable member of the team, and I am excited to see him take on the role of Chief Operating Officer.' In addition to his previous responsibilities overseeing quality, manufacturing, supply chain, and technical services operations, Mr. McGaugh now has oversight of Sonendo's capital and consumables sales teams and commercial operations. Mr. McGaugh has over 20 years overseeing global manufacturing operations. He joined Sonendo in May 2023 and has been instrumental in leading significant operational efficiencies with console assembly and procedure instrument margin contributions. Prior to his time at Sonendo, Mr. McGaugh served as a multi-site operational leader for Abbott Vascular. In addition to his experience at Abbott, Mr. McGaugh has held leadership roles at Boston Scientific and American Medical Systems. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices. For more information about Sonendo and the GentleWave System, please visit To find a GentleWave doctor in your area, please visit Forward Looking Statements This news release includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the Company's ability to continue to drive additional operating leverage and/or execute its plans to achieve profitability, whether as a result of Mr. McGaugh or otherwise. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions; speak only as of the date they are made; and, as a result, are subject to risks and uncertainties that may change at any time. Factors that could cause the Company's actual results to differ materially from these forward-looking statements are described in detail in the 'Risk Factors' section of the Company's Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on March 26, 2025. Such filings are available at The Company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Yahoo
33 minutes ago
- Yahoo
Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
LOUISVILLE, Ky., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Jazz Pharmaceuticals for Modeyso™ (dordaviprone). It is indicated for the treatment of adult and pediatric patients one year of age and older with diffuse midline glioma harboring an H3 K27M-mutation with progressive disease following prior therapy.1 This indication was approved based on five open-label, non-randomized clinical trials conducted in the U.S. (ONC006 [NCT02525692], ONC013 [NCT03295396], ONC014 [NCT03416530], ONC016 [NCT05392374], and ONC018 [NCT03134131]).1 'Onco360 is grateful for the opportunity to add Modeyso™ to our expansive portfolio of cancer and rare disease therapies as the first and only FDA-approved treatment for pediatric and adult patients with diffuse midline glioma,' said Benito Fernandez. 'We are proud and humbled to be part of this innovative treatment in support of patients, caregivers and families impacted by this devastating disease.' Dordaviprone is a protease activator of the mitochondrial caseinolytic protease P (ClpP) and inhibits dopamine D2 receptor (DRD2). In vitro, dordaviprone activates the integrated stress response, induces apoptosis, and alters mitochondrial metabolism, leading to restored histone H3 K27 trimethylation in H3 K27M-mutant diffuse glioma.1 The efficacy of Modeyso was evaluated in an integrated efficacy population of 50 adult and pediatric patients with recurrent H3 K27M-mutant diffuse midline glioma enrolled across five open-label, non-randomized clinical trials.1 The primary outcome was overall response rate (ORR) of 22% (95% CI: 12,36). The trial also demonstrated a duration of response of 10.3 months (95% CI: 7.3, 15.2) with 73% maintaining their response for at least six months and 27% for at least 12 months.1 Dordaviprone demonstrated manageable safety and tolerability adverse events. The most common adverse reactions (≥20 %; all causality) experienced with dordaviprone were fatigue, headache, nausea, vomiting, and musculoskeletal pain.1 Please see the full Prescribing Information for Modeyso. About Onco360 Oncology Pharmacy:Onco360 is the nation's largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Media Contact: Benito Fernandez, Chief Commercial References:1Modeyso™ (Dordaviprone) [Package Insert]. Palo Alto, CA. Jazz Pharmaceuticals. in to access your portfolio
Business Wire
3 hours ago
- Business Wire
Haig Partners Q2 2025 Haig Report ®: Dealer Profits Grow 20% Thanks to One Time Events; Buy-Sell Volume Declines but Values Remain Strong
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--The U.S. auto retail industry just closed one of its most profitable quarters in years — but the driving forces may surprise you. According to the newly released Q2 2025 Haig Report ® from Haig Partners, public dealer group profits per store jumped 20% year-over-year, fueled in part by two unique, short-term tailwinds: "...The fundamentals remain healthy, demand to buy dealerships is strong, and dealers have shown again and again that they can adapt to whatever the market throws at them.' Favorable comparisons to June 2024's CDK dealer management systems outage, which crippled many dealers' operations during Q2 last year. A pre-tariff buying surge after President Trump's April 2 'Liberation Day' announcement, pulling forward sales at strong margins. 'These unusual boosts have made Q2 look stronger than it may prove to be for the rest of the year,' said Alan Haig, President of Haig Partners. 'But the fundamentals remain healthy, demand to buy dealerships is strong, and dealers have shown again and again that they can adapt to whatever the market throws at them.' Additional highlights from the Q2 2025 Haig Report ®: Franchise Valuation Changes – Toyota, Kia, and Hyundai/Genesis saw multiple increases this quarter, reflecting strong demand and buyer appetite. Audi suffered a sharp valuation cut as prolonged sales declines and inventory imbalances eroded buyer interest. Blue Sky Values at Record Levels – Average dealership blue sky values remain about twice pre-COVID, a figure bolstered by steady multiples and strong earnings despite slower buy-sell volume. Market Momentum Shifts – Private buyers are showing broader appetite, while public groups are increasingly selective — favoring top-performing brands or strategic bolt-ons. Pipeline Strength – Haig Partners is advising on 67 dealership transactions signed or closed in 2025, 18% more than last year, outpacing the market's overall slowdown. Dealership Buy-Sell Market: Slower First Half, Set to Rebound? 192 U.S. rooftops changed hands in 1H 2025 — down 39.4% from last year's pace. Drivers of the slowdown: dealership buy-sell activity was still healthy in Q2, but more delayed closings experienced due to election-year uncertainty, tariff headlines, and a value gap between buyer and seller expectations. Outlook: A clearer political and economic landscape is expected to reignite activity in the second half, though volumes may be shifting back to a volume of 300-400 dealership sales per year compared to the 550-700 sales per year we experienced during the COVID era when valuations exploded. Economic & Operational Outlook Tariffs will have an impact in Q3. The OEMs have absorbed the cost of the tariffs so far, but we expect this will begin to change in Q3 as higher prices are subtly passed on to dealers and customers. Some brands will be hurt more than others, which could reshuffle dealership valuations. Interest rate cuts are increasingly likely later in 2025, which could boost more dealership buy-sell activity in the second half, not mention increased vehicle affordability for customers. EV mandates are gone, reducing risks for dealers in former CARB states. Now that dealers can sell the vehicles that consumers want to buy, dealers in CARB states can rest assured that their businesses will remain viable and valuable. The regulatory changes are likely to have an impact on everyone in auto retail. During an interview with Alan Haig, Senator Bernie Moreno stated, 'And I think right now, if I was in the car business today, I would be investing, I'd be buying, I'd be growing, because you take advantage of the fact that some people don't know how to manage change.' Haig Partners is seeing this spirit among the many dealership buyers it speaks with every week. Alan Haig said, 'Public and private buyers are trying to expand in this environment. Despite the unknown impact of tariffs, most of the larger groups are seeking to expand, and many smaller ones as well. And no one is calling us desperate to sell.' At Haig Partners, we are deeply grateful to the dealers, industry partners, and clients who place their trust in The Haig Report ® as a resource for navigating the dynamic automotive retail market. We recognize that selling a dealership is not only one of the most significant financial decisions in a dealer's career, but also one of the most personal. It is an honor to be invited into that process, to provide both the market insights that inform strategy and the expert guidance that helps our clients achieve the outcomes they deserve. Our team takes great pride in serving as a trusted advisor, combining decades of transaction experience with a deep respect for the legacy and future of each business we touch. We invite dealers considering a sale or acquisition to connect with us and explore how we can help maximize value and ensure a smooth, successful transition. About The Haig Report ® The Haig Report ®, the longest-published quarterly report tracking trends in auto retail and their impact on dealership values, includes data and analysis on the performance of auto dealerships, discusses noteworthy events impacting the automotive retail industry, identifies trends in the M&A market for dealerships, provides guidance on estimated value ranges for different franchises and shares an outlook for the automotive retail buy-sell market. The Haig Report ® is based on data gathered from reputable public sources and interviews with leading dealer groups and dealers, bankers, lawyers and accountants who specialize in auto retail. About Haig Partners Haig Partners is a leading buy-sell advisory firm that helps owners of higher-value dealerships maximize the value of their businesses when they are ready to sell. The team at Haig Partners has advised on the purchase or sale of more than 525 dealerships with a total value of over $10.6B. It has represented 30 dealership groups that qualify for the Top 150 Dealership Groups list published by Automotive News, more than any other firm. Clients of Haig Partners benefit from the group's collective experience as previous executives with leading companies such as Ally Financial, AutoNation, Bank of America, Credit Suisse, Deloitte, FORVIS, J.P. Morgan, the Sewell Automotive Companies and Toyota Financial Services. Leveraging its unmatched expertise and extensive relationships, Haig Partners guides clients to successful outcomes through a confidential and customized sales process. The firm authors The Haig Report ®, the leading industry quarterly report that tracks trends in auto retail and their impact on dealership values, and co-authors NADA's Guide, 'Buying and Selling a Dealership.' Haig Partners team members are frequent speakers at industry conferences and are regularly quoted in reputable media outlets, including Reuters, Forbes, The Wall Street Journal, The New York Times, CNBC, BBC, Automotive News, Wards, CarDealershipGuy and CBT News. For more information, visit
